Currently, the licensed biosimilars have gained the unique 4-letter suffix, but the older reference product may not have a suffix, for example; for example: adalimumab (Humira). Some older biosimilars are linked with the manufacturer (filgrastim-'sndz' for Sandoz), and some random (infliximab-d...
Then she also talked about biosimilars as well, not only the newer treatments, but some older agents, even have been available for several years now. We're really about to hit kind of a boom as far as a significant number of biosimilar agents in the autoimmune disease states that will be...
Specialty Area Biosimilars CardiorenalmetabolicCardiovascularChronic Kidney DiseaseDiabetesHeart FailureType 1 Diabetes DermatologyAlopeciaAtopic DermatitisPsoriasis Gastroenterology HematologyALL/AMLCLL/SLLGVHDHemophiliaMultiple MyelomaMyelodysplastic SyndromesMyeloproliferative NeoplasmsNon-Hodgkin LymphomaRare Blood ...
Choose Specialty Allergy Autoimmune Diseases Biosimilars COVID-19 Cannabidiol (CBD) Cardiology Compounding Continuous Glucose Monitoring Dermatology Diabetes Digestive Health Endocrinology Eye Health Generics HIV Headache and Migraine Immunization Infectious Disease Influenza Medical Devices Mental and Behavioral ...
With precision medicine, patients undergoing treatment are living longer without disease recurrence or progression and with fewer adverse effects, resulting in preservation of quality of life.
Choose Specialty Allergy Autoimmune Diseases Biosimilars COVID-19 Cannabidiol (CBD) Cardiology Compounding Continuous Glucose Monitoring Dermatology Diabetes Digestive Health Endocrinology Eye Health Generics HIV Headache and Migraine Immunization Infectious Disease Influenza Medical Devices Mental and Behavioral ...
Third, as some multinationals shift their focus toward specialty products, managing portfolios of drugs with very different commercial needs is becoming considerably more complex. Fourth, the war for talent continues, and is intensifying in some countries. Looking ahead...
For limited distribution drugs, there might be multiple other SPs that the consumer can use. But, those of you that follow my blog know that I’m a fan of the PBM model which has demonstrated savings in multiple studies, and I believe in limited distribution networks. I ...
Choose Specialty Allergy Autoimmune Diseases Biosimilars COVID-19 Cannabidiol (CBD) Cardiology Compounding Continuous Glucose Monitoring Dermatology Diabetes Digestive Health Endocrinology Eye Health Generics HIV Headache and Migraine Immunization Infectious Disease Influenza Medical Devices Mental and Behavioral ...